Nachrichten zur Biogen Inc. Aktie

Biogen up as Guggenheim upgrades citing full approval for Leqembi

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Soon After Novartis & Biogen Walked Away From Neurology Drug Partnerships, Sangamo Announces Major Restructuring

Sangamo Therapeutics Inc (NASDAQ: SGMO) announced cutting 27% of its workforce, prioritizing its pipeline, and changing its corporate structure to save…

The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio

Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog....…

Biogen: Neues Kursziel

New York (www.aktiencheck.de) - Rating-Update: Das Anlagevotum der Analysten von Morgan Stanley für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Form 10-Q BIOGEN INC. For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen: Glanzlose Zahlen überschatten Zulassung - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Biogen-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Biogen-Aktie (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

Biogen Wins US Approval for Drug to Treat Rare Form of ALS

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kampf gegen ALS: Biogen und dieser Partner erhalten US-Zulassung

Die Amyotrophe Lateralsklerose (ALS) zählt zu den schwerwiegendsten Erkrankungen des zentralen und peripheren Nervensystems – und der medizinische Bedarf ist…

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS

CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food…

Biogen, Ionis win FDA nod for ALS therapy Qalsody

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease

The FDAs approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits....…

Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs

Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading....…

Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023,…

Biogen tops 1Q forecast despite sales slip for key products

Biogen beat Wall Streets first-quarter expectations even as revenue from the drugmakers biggest product group tumbled...…

Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do…

Biogen Q1 Results Top Estimates; Reaffirms FY23 Outlook

WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter…

Biogen tops estimates as revenue slides 3% from a year ago

Biogen Inc. BIIB said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter,…

Alzheimers, Depression Drugs Are in Focus as Biogen Reports Results

Investors already know that the biotech company's base business is shrinking, so few are looking there for growth....…

Biogen Q1 results in focus amid Leqembi conundrum, ALS drug future

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Better Big Biotech Buy: Biogen vs. Vertex

One is slightly cheaper than the other....…

Biogen: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Argus Research stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

Is Biogen Stock a Buy Now?

The companys fascinating saga in the Alzheimers disease drug market continues....…

Leqembi Sales To Propel Biogen Stock To New Heights, Says Bullish Analyst

Latest Ratings for BIIB DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy View…

Biogen: Alzheimer-Medikament könnte richtig Feuer in der Bilanz entfachen - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Biogen-Aktienanalyse von "Der Aktionär": Martin Weiss, stellvertretender Chefredakteur vom Anlegermagazin "Der Aktionär", nimmt die Biogen-Aktie (ISIN: US09062X1037, WKN:…

Opening Bell: JPMorgan, Netflix, WW, Biogen, Alphabet, Microsoft, First Solar

Vor dem Wochenende drückten schwache Einzelhandelsumsätze auf die Stimmung der Anleger. Der Dow Jones gab 0,4 Prozent ab, der S&P…

Biogen: Kursziel reduziert

New York (www.aktiencheck.de) - Rating-Update: Matthew Harrison, Analyst von Morgan Stanley, bewertet die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Insiderhandel: Head of Development verkauft Aktien von Biogen im Wert von 25.217$

Singhal, Priya - Vorstand - Tag der Transaktion: 2023-04-04...…

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day....…

Biogen names Adam Keeney to head corporate development

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen Appoints Adam Keeney as Head of Corporate Development

CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam…

Legend Biotech appoints former CEO of Biogen as advisor

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Price Over Earnings Overview: Biogen

Eisai, Biogen Present Lecanemab New Analyses In Phase 3 Trial; Detailed Analyses In Phase IIb Trial

WESTON (dpa-AFX) - Drug makers Biogen Inc. (BIIB) and Japans Eisai Co., Ltd. (ESALY.PK, ESALF.PK) announced Friday new analyses from…

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Insiderhandel: Head of Development verkauft Aktien von Biogen im Wert von 153.394$

Singhal, Priya - Vorstand - Tag der Transaktion: 2023-03-28...…

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day....…

Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions

WESTON (dpa-AFX) - Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced…

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day....…

Biogen Unusual Options Activity

Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA

The FDA committee supports an accelerated approval of Biogens (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the…

Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS

WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) announced the outcome of the U.S. Food and Drug Administrations Peripheral and…

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a…

Biogen ALS drug considered not effective by FDA advisory panel

Biogen Inc. BIIB received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug…

Biogen ALS drug tofersen earns mixed voting by FDA advisory panel

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA advisors reject Biogens ALS drug for rare and aggressive form of the disease

FDA advisors voted against Biogens investigational ALS drug, which could become the first to target a genetic cause of the…

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session....…

Wall Street predicts approval for another ALS drug

An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to…

FDA staff says Biogens ALS drug may have a clinical benefit on a rare form of the disease

The FDA staff on Monday said Biogens investigational ALS drug tofersen may have a "clinical benefit" on a rare and…

Biogen Data Suggest ALS Drug Has Treatment Effect, FDA Staff Say

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA scientists weigh potential effect of Biogen ALS drug ahead of advisory meeting

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

dpa-AFX ProFeed